• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性瘙痒:一篇叙述性综述。

Chronic pruritus: a narrative review.

作者信息

Criado Paulo Ricardo, Jardim Criado Roberta Fachini, Ianhez Mayra, Miot Hélio Amante

机构信息

Centro Universitário Faculdade de Medicina do ABC, Santo André, SP, Brazil; Faculdade de Ciências Médicas de Santos (Fundação Lusíada), Santos, SP, Brazil.

Alergoskin Alergia e Dermatologia, UCARE Center and ADCARE, Santo André, São Paulo, Brazil.

出版信息

An Bras Dermatol. 2025 May-Jun;100(3):487-519. doi: 10.1016/j.abd.2024.09.008. Epub 2025 May 3.

DOI:10.1016/j.abd.2024.09.008
PMID:40320333
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12234205/
Abstract

Chronic pruritus encompasses a manifestation of several cutaneous, allergic, infectious, neurological, psychological, and systemic conditions, whose etiological investigation and therapeutic strategy can be challenging. This comprehensive review aims to enhance the understanding of pruritus by highlighting important elements in its pathogenesis, including keratinocytes, Merkel cells and mast cells, nerve fibers, histaminergic and nonhistaminergic pathways, and the interaction of itch signals with the central nervous system. Diagnostic evaluation of chronic pruritus may require a meticulous approach, guided by the identification of skin lesions or signs/symptoms of underlying systemic diseases. A comprehensive evaluation, including a detailed medical history, thorough physical examination, and appropriate laboratory and imaging tests, often supplemented by skin biopsy and direct immunofluorescence, is essential. Treatment strategies for chronic pruritus should be individualized based on the etiology identified. General measures, such as emollients, serve as initial interventions, followed by targeted approaches. Topical corticosteroids, calcineurin inhibitors, phototherapy, and systemic immunosuppressants address cutaneous inflammation. Antihistamines, antidepressants, and immunosuppressants may be employed based on the specific etiology. Emerging therapies, including biologic drugs and JAK inhibitors, have potential in refractory cases.

摘要

慢性瘙痒是多种皮肤、过敏、感染、神经、心理和全身性疾病的一种表现,对其病因进行调查并制定治疗策略可能具有挑战性。这篇综述旨在通过强调瘙痒发病机制中的重要因素来增进对瘙痒的理解,这些因素包括角质形成细胞、默克尔细胞和肥大细胞、神经纤维、组胺能和非组胺能途径,以及瘙痒信号与中枢神经系统的相互作用。慢性瘙痒的诊断评估可能需要一种细致的方法,以识别皮肤病变或潜在全身性疾病的体征/症状为指导。全面评估,包括详细的病史、全面的体格检查以及适当的实验室和影像学检查,通常辅以皮肤活检和直接免疫荧光检查,至关重要。慢性瘙痒的治疗策略应根据所确定的病因进行个体化。一般措施,如润肤剂,作为初始干预措施,随后采取针对性方法。局部皮质类固醇、钙调神经磷酸酶抑制剂、光疗和全身性免疫抑制剂可解决皮肤炎症问题。抗组胺药、抗抑郁药和免疫抑制剂可根据具体病因使用。包括生物药物和JAK抑制剂在内的新兴疗法在难治性病例中具有潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/c84b3a739bbe/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/a116e00a5e05/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/2195a577ef3b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/bd50914470de/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/6132bb98d50a/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/c84b3a739bbe/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/a116e00a5e05/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/2195a577ef3b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/bd50914470de/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/6132bb98d50a/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b407/12234205/c84b3a739bbe/gr5.jpg

相似文献

1
Chronic pruritus: a narrative review.慢性瘙痒:一篇叙述性综述。
An Bras Dermatol. 2025 May-Jun;100(3):487-519. doi: 10.1016/j.abd.2024.09.008. Epub 2025 May 3.
2
Clinical Practice Updates: AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.临床实践更新:美国胃肠病学会关于可弯曲性埃勒斯-当洛综合征的胃肠道表现及自主神经或免疫功能障碍的临床实践更新:专家综述
Clin Gastroenterol Hepatol. 2025 May 19. doi: 10.1016/j.cgh.2025.02.015.
3
Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin.显性营养不良型大疱性表皮松解症与糖酵解活性的 GATA3+T 辅助 2 细胞相关,这些细胞可能导致皮损皮肤的瘙痒。
Br J Dermatol. 2024 Jul 16;191(2):252-260. doi: 10.1093/bjd/ljae110.
4
Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors.度普利尤单抗治疗慢性瘙痒症和慢性特发性瘙痒症的疗效:现有证据的系统评价及应答预测因素分析。
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1541-1551. doi: 10.1111/jdv.18221. Epub 2022 May 31.
5
Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥ 13 years: efficacy and safety data from a phase II/III study.≥13岁结节性痒疹患者长期(68周)使用奈莫利单抗和外用皮质类固醇:一项II/III期研究的疗效和安全性数据
Br J Dermatol. 2025 Jun 20;193(1):56-65. doi: 10.1093/bjd/ljaf045.
6
Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.尼莫利珠单抗联合外用皮质类固醇治疗结节性痒疹的疗效和安全性:一项在年龄≥13 岁患者中进行的随机、双盲、安慰剂对照的 II/III 期临床研究结果。
Br J Dermatol. 2024 Jul 16;191(2):200-208. doi: 10.1093/bjd/ljae131.
7
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
8
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
9
Topical anti-inflammatory treatments for eczema: network meta-analysis.外用抗炎治疗湿疹:网状荟萃分析。
Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015064. doi: 10.1002/14651858.CD015064.pub2.
10
Interleukin 31 and skin diseases: A systematic review.白细胞介素31与皮肤疾病:一项系统综述。
Allergy Asthma Proc. 2017 Nov 1;38(6):401-408. doi: 10.2500/aap.2017.38.4080.

引用本文的文献

1
Pruritus in Palliative Care: A Narrative Review of Essential Oil-Based Strategies to Alleviate Cutaneous Discomfort.姑息治疗中的瘙痒:基于精油缓解皮肤不适策略的叙述性综述
Diseases. 2025 Jul 23;13(8):232. doi: 10.3390/diseases13080232.

本文引用的文献

1
Emerging concepts in neuropathic and neurogenic itch.神经病理性瘙痒和神经源性瘙痒的新观点。
Ann Allergy Asthma Immunol. 2023 Nov;131(5):561-566. doi: 10.1016/j.anai.2023.08.008. Epub 2023 Aug 18.
2
An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma.原发性皮肤 T 细胞淋巴瘤瘙痒机制及其潜在治疗方法的最新进展。
Clin Exp Med. 2023 Dec;23(8):4177-4197. doi: 10.1007/s10238-023-01141-x. Epub 2023 Aug 9.
3
JAK-STAT pathway inhibitors in dermatology.JAK-STAT 通路抑制剂在皮肤病学中的应用。
An Bras Dermatol. 2023 Sep-Oct;98(5):656-677. doi: 10.1016/j.abd.2023.03.001. Epub 2023 May 23.
4
New small molecules in dermatology: for the autoimmunity, inflammation and beyond.皮肤病学中的新型小分子药物:针对自身免疫、炎症及其他领域。
Inflamm Res. 2023 Jun;72(6):1257-1274. doi: 10.1007/s00011-023-01744-w. Epub 2023 May 22.
5
Clinical aspects and management of chronic itch.慢性瘙痒的临床特点与管理
J Allergy Clin Immunol. 2023 Jul;152(1):1-10. doi: 10.1016/j.jaci.2023.04.018. Epub 2023 May 11.
6
[Translated article] Pruritus in Dermatology: Part 1-General Concepts and Pruritogens.[译文] 皮肤科的瘙痒症:第一部分——一般概念和致痒原。
Actas Dermosifiliogr. 2023 Jun;114(6):T512-T522. doi: 10.1016/j.ad.2023.05.013. Epub 2023 May 10.
7
Chronic pruritus: From pathophysiology to drug design.慢性瘙痒:从病理生理学到药物设计。
Biochem Pharmacol. 2023 Jun;212:115568. doi: 10.1016/j.bcp.2023.115568. Epub 2023 Apr 26.
8
Associations between bullous pemphigoid and hematological diseases: Literature review on mechanistic connections and possible treatments.大疱性类天疱疮与血液系统疾病的相关性:对发病机制关联及可能治疗方法的文献综述。
Front Immunol. 2023 Mar 8;14:1155181. doi: 10.3389/fimmu.2023.1155181. eCollection 2023.
9
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.人源单克隆抑瘤素M受体β抗体维卡瑞单抗治疗中度至重度结节性痒疹的疗效和安全性:一项随机、双盲、安慰剂对照的2a期研究
EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. eCollection 2023 Mar.
10
Itch and Janus Kinase Inhibitors.瘙痒和 Janus 激酶抑制剂。
Acta Derm Venereol. 2023 Feb 15;103:adv00869. doi: 10.2340/actadv.v103.5346.